Update 2020: Management of Non-Small Cell Lung Cancer

Mariam Alexander, So Yeon Kim, Haiying Cheng

Research output: Contribution to journalReview articlepeer-review

190 Scopus citations


The past decade has seen a revolution of new advances in the management of non-small cell lung cancer (NSCLC) with remarkable progresses in screening, diagnosis, and treatment. The advances in systemic treatment have been driven primarily by the development of molecularly targeted therapeutics, immune checkpoint inhibitors, and anti-angiogenic agents, all of which have transformed this field with significantly improved patient outcomes. This review will address updates in lung cancer screening, liquid biopsy, and immunotherapy in the front-line setting. We discuss recent advances and highlight the plethora of new approvals of molecular-targeted therapy for subgroups of NSCLC patients with sensitizing EGFR, ALK, ROS1, RET, BRAF V600E, MET, and NTRK alterations.

Original languageEnglish (US)
Pages (from-to)897-907
Number of pages11
Issue number6
StatePublished - Dec 2020


  • Immune checkpoint inhibitors
  • Lung cancer
  • Targeted therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Update 2020: Management of Non-Small Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this